The emergence of the COVID-19 pandemic has caused fatalities to reach the tens of thousands worldwide. The first set of evidence reported from clinical studies suggested that the main cause of mortality was a combination of respiratory failure and systemic inflammatory response syndrome. Subsequently, most of the therapies were directed against the aforementioned difficulties (
7). However, more recent studies suggest that the virus could also affect the circulatory system; with case reports suggesting that the virus causes myocarditis, in addition to affecting the pump function of the left ventricle (
8). Additionally, there is echocardiographic evidence that suggests that the virus can even have an effect on the function of the right ventricle. A limited number of case reports have suggested that one of the mechanisms resulting in this loss of function could be pulmonary thromboembolism, leading to right ventricle straining. Xie et al. presented two cases of patients with COVID-19, who deteriorated and had elevated D-dimer levels. The patients developed signs of pulmonary thromboembolism PTE in their second and sixth day of hospitalization, and were subsequently put on therapy. Both patients had moderate to severe bilateral lung involvement prior to the PTE (
9). Danzi et al. reported the case study of a 75-year-old patient with severe bilateral involvement, with signs of infarct in the basal regions of the right ventricle. An echocardiography showed a hypokinetic right ventricle and a mean pulmonary artery pressure of 60 mmHg (
10). More concrete evidence of this is presented in a study conducted by Klok et al. (
11). They found that out of the 184 patients hospitalized in the ICU due to COVID-19, 31% (95%CI: 17% - 37%) showed signs of thrombotic disease, with pulmonary thromboembolism being the most common. All of the patients included in the study had received standard doses of prophylactic anticoagulants, but had developed thrombotic events regardless. Thus, the authors concluded that high-dose prophylaxis should be considered for these patients (
11).
It is important to note that pregnant patients have an increased susceptibility to thrombosis formation, and any further pro-thrombosis factors may severely predispose them to inappropriate thrombosis formation (
12). Clinicians should pay more attention to the acute deterioration of COVID-19 pneumonia in pregnant patients, as it may represent a potentially life-threatening condition such as PTE.